The United States of America has the best medical treatment in the world, but like most things with quality it is not cheap. Advocacy groups like the Commonwealth Fund focus on high average cost in their cultural efforts to nationalize the health care system, but they rarely cover the real reason health care coverage is high - too much is included and hospitals and doctors have a defensive medicine culture due to a hyperactive malpractice system.
If you don't cover every possible test, and something goes wrong, you will get sued. And now, with greater government involvement, even more doctors will be trained in a 'teach to the protocol' environment and run down a checklist of things they know are not relevant.
Costs are going to go up a lot before we get reform in defensive medicine and malpractice lawsuits. Then they can come down. But in a world without lobbyists, researchers at Johns Hopkins Bayview Medical Center tested a simple tactic that, if it became the template for medicine overall, could significantly reduce the number of unnecessary blood tests - and their cost - to assess symptoms of heart attack and chest pain and achieve a large decrease in patient charges.
The team provided information and education to physicians about proven testing guidelines and made changes to the computerized provider order entry system at the medical center, part of the Johns Hopkins Health System. The guidelines call for more limited use of blood tests for so-called cardiac biomarkers. A year after implementation, the guidelines saved the medical center an estimated $1.25 million in laboratory charges.
In this case, part of the focus was on tests to assess levels of troponin, a protein whose components increase in the blood when heart muscle is damaged. Frequently, troponin tests are repeated four or more times in a 24-hour period, which studies have suggested is excessive, and they are often done along with tests for other biomarkers that are redundant.
These interventions reduced overuse of troponin and other biomarker testing without compromising patient care. If adopted widely, the team says, cost savings could be substantial.
"This study has broader implications for the health care system, as most hospitals continue to redundantly test people for chest pain and other symptoms," says report author Jeffrey C. Trost, M.D., an assistant professor of medicine, director of the cardiac catheterization laboratory and co-director of interventional cardiology at Johns Hopkins Bayview Medical Center. "Implementing our interventions could save patients and society a significant amount of money, potentially several billion dollars."
For the study, the Johns Hopkins team set out to lower the rate at which doctors order cardiac biomarker testing for the diagnosis of acute coronary syndrome by basing the desired rate on scientific evidence.
In 2010, the researchers report, more than 17 million patients with chest pain visiting an emergency department in the United States received cardiac biomarker testing.
Between August and October 2011 at Johns Hopkins Bayview Medical Center, the team introduced written institutional guideline and changes to the computerized provider order entry system designed to reduce redundant testing.
The new guidelines suggest ordering troponin alone, without creatine kinase or creatine kinase-MB, for patients suspected to have acute coronary syndrome. It specifies that troponin should be assessed no more than three times over 18 to 24 hours.
Internists and emergency department doctors attended informational sessions to learn the guidelines, and all received quick reference cards summarizing them.
In the computerized provider order entry system, orders for creatine kinase and creatine kinase-MB were removed from all standardized order sets. Troponin orders were removed from all order sets, except two that are used for evaluating new acute coronary syndrome symptoms. A pop-up warning alerted providers when a troponin test was ordered sooner than six hours after a previous one, or when a provider attempted to order creatine kinase or creatine kinase-MB at the same time.
Twelve months after the interventions, doctors' use of the new guidelines increased from 57.1 percent to 95.5 percent and led to a 66 percent decrease in the absolute number of tests ordered. Also, there was a small but statistically significant increase in the primary or secondary diagnosis of acute coronary syndrome after the intervention period.
Lead author Marc R. Larochelle, M.D., an internal medicine resident at Johns Hopkins Bayview Medical Center during the study and now a fellow in general medicine at Harvard Medical School, says that, "Through review of available evidence and reflection on our own practice, I believe we can proactively identify many practices that may be unnecessary and wasteful. We have demonstrated proof of concept that doctors can be leaders in delivering improved value for our patients and health care systems."
Larochelle and Trost believe that provider education and changes to the ordering system were effective in aligning physician ordering behavior with evidence-based guidelines and reducing wasteful health care spending.
Article: "Reducing Excess Cardiac Biomarker Testing at an Academic Medical Center", Journal of General Internal Medicine. Source: Johns Hopkins Medicine